Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Foundation Medicine, Inc. (NASDAQ: FMI).

Full DD Report for FMI

You must become a subscriber to view this report.


Recent News from (NASDAQ: FMI)

The No BS Report, Week 12: Living In Yawnsville With Little But Gains
Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Right now you can get a no-obligation free trial to the service for two weeks. Welcome to an...
Source: SeekingAlpha
Date: May, 06 2018 08:58
Foundation Medicine's (FMI) CEO Troy Cox on Q1 2018 Results - Earnings Call Transcript
Foundation Medicine, Inc. (FMI) Q1 2018 Results Earnings Conference Call May 02, 2018, 04:30 PM ET Executives Jason Ryan - CFO & Principal Accounting Officer Susan Hager - SVP of Corporate Communications & Government Affairs Tom Civik - Chief Commercial Officer Troy Cox...
Source: SeekingAlpha
Date: May, 02 2018 23:17
Foundation Medicine beats by $0.08, beats on revenue
Foundation Medicine (NASDAQ: FMI ): Q1 EPS of -$1.02 beats by $0.08 . More news on: Foundation Medicine, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 02 2018 16:06
Foundation Medicine Announces 2018 First Quarter Results and Recent Highlights
Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the first quarter ended March 31, 2018. Highlights for the quarter included: Posted revenue of $52.8 million, 101% year-over-year growth; Reported 21,861 clinical tests, 57% year-over-...
Source: Business Wire
Date: May, 02 2018 16:01
Foundation Medicine Launches Gene Expression Profiling Program to Identify Known and Novel Biomarkers in Advanced Cancer
Foundation Medicine, Inc. (NASDAQ:FMI) today announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development. This initiative, which provides a natural complement to Foundation Medicine’s comprehensive genomic profili...
Source: Business Wire
Date: May, 02 2018 07:00
The No BS Report, Week 11: Rising Tides And Sinking Ships?
Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Right now you can get a no-obligation free trial to the service for two weeks. Welcome to an...
Source: SeekingAlpha
Date: April, 29 2018 14:04
Foundation Medicine, Roche and DIAN Diagnostics Collaborate to Advance Personalized Cancer Care in China
--DIAN Designated Roche’s and Foundation Medicine’s Exclusive Clinical Sequencing Partner in China-- --Roche will Commercialize Foundation Medicine’s Comprehensive Genomic Profiling Tests in China-- Foundation Medicine, Inc. , (NASDAQ:FMI), F. Hoffmann-La Ro...
Source: Business Wire
Date: April, 26 2018 18:00
Foundation's new liquid biopsy test designated for accelerated review in U.S.
Foundation Medicine (NASDAQ: FMI ) is up  3%  premarket, albeit on only 231 shares, on the heels of its announcement that its new liquid biopsy test, an expanded version of its FoundationACT assay, has been designated a Breakthrough Device by the FDA. More news on: Foundation...
Source: SeekingAlpha
Date: April, 26 2018 08:05
Foundation Medicine's New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for its new liquid biopsy assay, which is an expanded version of its FoundationACT ® assay. Th...
Source: Business Wire
Date: April, 26 2018 07:00
Foundation Medicine: To Profit From The Increasing Trend Of Personalized Treatment
Our game is to recognize a big idea when it comes along, when one doesn’t come along very often. Opportunity comes to the prepared mind. - Charlie Munger Foundation Medicine (NASDAQ: FMI ) is a highly interesting bioscience that came to our attention by a subscriber of Integrat...
Source: SeekingAlpha
Date: April, 23 2018 02:23

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1780.5079.7581.0078.0599198,062
2017-05-1635.6536.0036.0035.375171,781
2017-05-1535.4035.5535.8033.95453,847
2017-05-1233.0033.2034.325332.90190,943
2017-05-1134.1532.9534.51632.50325,837

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-07-3042,56288,85247.9021Short
2018-07-2729,05872,64340.0011Short
2018-07-2640,435126,90331.8629Cover
2018-07-2595,259138,08668.9853Short
2018-07-2446,558193,86724.0154Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FMI.


About Foundation Medicine, Inc. (NASDAQ: FMI)

Logo for Foundation Medicine, Inc. (NASDAQ: FMI)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: FMI)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 02 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 27 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 03 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 19 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 07 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 07 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 07 2018

       

       


      Daily Technical Chart for (NASDAQ: FMI)

      Daily Technical Chart for (NASDAQ: FMI)


      Stay tuned for daily updates and more on (NASDAQ: FMI)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: FMI)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FMI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of FMI and does not buy, sell, or trade any shares of FMI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/